Parkinson's disease and levodopa. A five-year follow-up and review.
D000203:Activities of Daily Living; D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D001264:Athetosis / Q000139:chemically induced; D001479:Basal Ganglia / Q000503:physiopathology; D002819:Chorea / Q000139:chemically induced; D003342:Corpus Striatum / Q000503:physiopathology; D003704:Dementia / Q000209:etiology; D003863:Depression / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D012725:Sexual Behavior / Q000187:drug effects; D013378:Substantia Nigra / Q000503:physiopathology; D014839:Vomiting / Q000139:chemically induced
D007980:Levodopa